Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
- improving the appropriate prescribing and use of medications
- increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data
- reducing drug system duplication and lack of coordination
CADTH adopted the new name Canada’s Drug Agency (CDA-AMC) as of May 1, 2024. An official launch will occur later this year.

The CIHR Institute of Cancer Research is pleased to announce the open call for applications for its 2025 Early Career Researcher (ECR) Workshop, in partnership with the Canadian Cancer Research Alliance, Canadian Cancer Society, Cancer Research Society, Ontario Institute f...
Abstract submission for the 2023 Canadian Cancer Research Conference is now open. Submissions from the entire spectrum of cancer research topics are welcome. Abstract submission deadline: Friday, June 9, 2023. For more information, go to